Inflammatory Disease News and Research

RSS

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in sugar and fats. In a new research report published in the December 2013 issue of The FASEB Journal, scientists show that there is an abnormal amount of an inflammatory protein called PAR2 in the abdominal fat tissue of overweight and obese humans and rats.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Smaller micropolitan areas of the U.S. have very few rheumatologists

A novel study published in the American College of Rheumatology journal, Arthritis & Rheumatism, shows that smaller micropolitan areas of the U.S.-those with less than 50,000 people-have very few or no practicing adult rheumatologist. In some of these areas, individuals have to travel more than 200 miles to reach the closest rheumatologist.

27 Nov 2013

Discovery could rev up body's immune response to infection, autoimmune diseases

UT Southwestern Medical Center researchers report that disrupting the light-dark cycle of mice increased their susceptibility to inflammatory disease, indicating that the production of a key immune cell is controlled by the body's circadian clock.

8 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

Disruption of brain signals contributes to increased pain sensitivity in fibromyalgia patients

New research indicates that a disruption of brain signals for reward and punishment contributes to increased pain sensitivity, known as hyperalgesia, in fibromyalgia patients. Results published in Arthritis & Rheumatism, a journal of the American College of Rheumatology, suggest that this altered brain processing might contribute to widespread pain and lack of response to opioid therapy in patients with fibromyalgia.

5 Nov 2013

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Researchers identify risk factors, protective medication for people living with lupus

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.

28 Oct 2013

Study: Headache is not a sign of lupus activity

Headache is common among patients with system lupus erythematosus according to new research published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

28 Oct 2013

Biomarker may predict poor pregnancy outcomes in lupus patients

Researchers at Hospital for Special Surgery in New York City have identified a biomarker that may predict poor pregnancy outcomes in lupus patients.

28 Oct 2013

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

28 Oct 2013

Children born to mothers with lupus have twice the risk of autism spectrum disorders

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

28 Oct 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

New injection device to reduce fear and pain of injecting modern medicines

...

15 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Inflammatory Disease News and Research

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Scientists identify key factor for limiting inflammatory responses, particularly in skin

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Smaller micropolitan areas of the U.S. have very few rheumatologists

Discovery could rev up body's immune response to infection, autoimmune diseases

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

Disruption of brain signals contributes to increased pain sensitivity in fibromyalgia patients

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Researchers identify risk factors, protective medication for people living with lupus

Study: Headache is not a sign of lupus activity

Biomarker may predict poor pregnancy outcomes in lupus patients

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Children born to mothers with lupus have twice the risk of autism spectrum disorders

NHMRC awards over $6M for Griffith University research projects

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

New injection device to reduce fear and pain of injecting modern medicines

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News